Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain function

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,111 result(s) found for: Brain function. Displaying page 3 of 56.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-000113-38 Sponsor Protocol Number: UCL/05/177 Start Date*: 2007-03-07
    Sponsor Name:University College London
    Full Title: A randomised phase II double blind placebo controlled trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) with mul...
    Medical condition: Advanced non-small cell lung cancer with multiple brain metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2016-003724-23 Sponsor Protocol Number: GI-AU-NMH-2016-01 Start Date*: 2017-12-28
    Sponsor Name:The George Institute for Global Health, University of New South Wales
    Full Title: Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial
    Medical condition: Patients with a history of acute stroke due to Intracranial Haemorrhage with mild to moderately high blood pressure.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10019016 Haemorrhagic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-021191-29 Sponsor Protocol Number: ML25432 Start Date*: 2011-03-23
    Sponsor Name:ROCHE
    Full Title: A multicenter, open label study to assess the effect of trastuzumab + Whole Brain Radiotherapy (WBRT) on brain metastases from HER-2 positive breast cancer.
    Medical condition: Stage IV, HER-2 positive breast cancer patients with brain metastasis and who are eligible for WBRT.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014544-11 Sponsor Protocol Number: C10953/3069/ES/MN Start Date*: 2010-05-21
    Sponsor Name:Cephalon Inc
    Full Title: Estudio abierto de 12 meses para la evaluación de la seguridad, la tolerabilidad y la eficacia de armodafinil (150 mg/día y 250 mg/día) como tratamiento para pacientes con somnolencia excesiva asoc...
    Medical condition: Pacientes con somnolencia excesiva asociada a un trauma craneo-cerebral no penetrante leve o moderado. Excessive sleepiness accociated with mild or moderate closed traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060690 Traumatic brain injury LLT
    12.0 10015595 Excessive daytime sleepiness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003199-56 Sponsor Protocol Number: CA209-322 Start Date*: 2016-01-08
    Sponsor Name:University Medical Center Groningen
    Full Title: An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of nivolumab/ipilimumab combination therapy in metastatic melanoma patients with symptomatic brain metastases.
    Medical condition: Metastatic (stage IV) melanoma with symptomatic brain metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-001912-20 Sponsor Protocol Number: 48431 Start Date*: 2018-02-26
    Sponsor Name:University Medical Center Utrecht, The Netherlands
    Full Title: Adult mesenchymal stem cells to regenerate the neonatal brain: the PASSIoN trial (Perinatal Arterial Stroke treated with Stem cells IntraNasally)
    Medical condition: Perinatal arterial Ischemic Stroke (PAIS)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003137-42 Sponsor Protocol Number: EPIFLUX Start Date*: 2020-04-10
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy
    Medical condition: Investigation in healthy volunteers and epilepsy patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024477-39 Sponsor Protocol Number: 105MS302 Start Date*: 2011-05-06
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) ES (Completed) BG (Completed) EE (Completed) GB (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-000625-27 Sponsor Protocol Number: EAC01 Start Date*: 2021-06-11
    Sponsor Name:Oulu Functional NeuroImaging, MRC/MIPT, Oulu University Hospital
    Full Title: Augmenting glymphatic function with electroacoustic treatment.
    Medical condition: Investigated people are healthy adults.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004398-41 Sponsor Protocol Number: IJB-BC-TDM1BM-2016 Start Date*: 2018-01-26
    Sponsor Name:Institut Jules Bordet
    Full Title: Multicentre, non-randomised, open-label, single agent phase II study to determine the clinical benefit of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer patients with brain...
    Medical condition: Metastatic HER2-positive breast cancer with brain metastasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003103-27 Sponsor Protocol Number: UoL001152 Start Date*: 2017-01-19
    Sponsor Name:University of Liverpool
    Full Title: A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy
    Medical condition: HER2-positive breast cancer with brain metastasis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005616-29 Sponsor Protocol Number: FOCUS2012 Start Date*: 2012-02-03
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: A multicentre randomised trial to establish the effect(s) of routine administration of Fluoxetine for six months in patients with a recent stroke
    Medical condition: acute stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    14.1 10029205 - Nervous system disorders 10019016 Haemorrhagic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001438-25 Sponsor Protocol Number: VWM1 Start Date*: 2020-04-21
    Sponsor Name:VU University Medical Center
    Full Title: A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM)
    Medical condition: Vanishing white matter
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006452-22 Sponsor Protocol Number: maple b Start Date*: 2009-04-01
    Sponsor Name:Academic Medical Centre
    Full Title: The effects of melatonin in the treatment of delirium
    Medical condition: Delirium in elderly patients (65 yrs and older) acutely admitted to the ward of internal medicine.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012218 Delirium LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023837-45 Sponsor Protocol Number: BRF113929 Start Date*: 2011-01-26
    Sponsor Name:GlaxoSmithKline
    Full Title: BRF113929: A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Naïve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to...
    Medical condition: BRAF V600E or V600K mutation-positive metastatic melanoma to the brain
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003873-41 Sponsor Protocol Number: 14-23-16/07 Start Date*: 2015-07-09
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial
    Medical condition: Eligible patients with histologically/cytologically proven primary tumors of the prostate, esophagus, brain or rectum or metastatic disease to the brain (originating from breast, lung or colorectal...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003203-14 Sponsor Protocol Number: TUXEDO-2 Start Date*: 2023-05-02
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Medizin I, Onkologie
    Full Title: Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases
    Medical condition: triple negative breast cancer with newly diagnosed or progressing brain metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002801-12 Sponsor Protocol Number: ONT-380-206 Start Date*: 2017-08-07
    Sponsor Name:Seagen Inc.
    Full Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastati...
    Medical condition: Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) BE (Completed) DK (Completed) FR (Completed) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005024-37 Sponsor Protocol Number: 202100647 Start Date*: 2022-01-24
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease
    Medical condition: - Alzheimer's disease - Mild Cognitive Impairment - Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000981-41 Sponsor Protocol Number: TUXEDO-1 Start Date*: 2020-06-26
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Mdizin I, Onkologie
    Full Title: Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases
    Medical condition: HER2-positive Breast Cancer with newly diagnosed or progressing Brain Metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 11:50:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA